查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961398

良性前列腺增生治療設備市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用戶、地區和競爭格局分類，2021-2031年

Benign Prostatic Hyperplasia Treatment Equipment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球良性攝護腺增生 (BPH) 治療設備市場預計將從 2025 年的 115.6 億美元成長到 2031 年的 149.8 億美元，複合年成長率為 4.41%。

該市場涵蓋用於治療良性前列腺增生（BPH）的微創和外科手術醫療設備，包括電切鏡、雷射系統和射頻消融設備等技術。推動這一市場成長的主要因素是全球人口快速老化以及人們越來越傾向於選擇能夠加速患者康復的微創手術。老年男性中BPH的高發生率是造成此需求的主要原因。例如，美國泌尿系統協會在2024年報告稱，65歲及以上男性中良性前列腺增生及相關下泌尿道症狀的盛行率在29%至35%之間。

市場概覽
預測期 2027-2031
市場規模：2025年 115.6億美元
市場規模：2031年 149.8億美元
複合年成長率：2026-2031年 4.41%
成長最快的細分市場 雷射設備
最大的市場 北美洲

儘管市場需求強勁，先進外科技術所需的巨額資本投資仍是市場擴張的一大障礙。安裝和維護最新雷射主機和機器人系統的高成本會限制其普及率，尤其是在採購預算緊張的醫療機構。因此，在成本敏感地區，這種經濟障礙往往迫使醫療機構依賴傳統的（效率較低的）方法，減緩了新設備解決方案的推廣應用。

市場促進因素

良性前列腺增生（BPH）盛行率的上升，其根本原因在於全球男性人口老化，這需要持續增加診斷和治療設備的應用。隨著預期壽命的延長，需要干預治療下泌尿道症狀的患者人數不斷成長，醫療機構必須升級泌尿系統，以滿足這一可預見且不斷擴大的切除和消融系統市場需求。根據聯合國2024年7月發布的《2024年世界人口展望概要》，預計到2050年，65歲及以上人口的比例將達到約16%，這將顯著擴大BPH的主要風險人口。

隨著人口結構的變化，由於患者希望縮短復原時間，對微創、非手術治療方法的治療方法顯著增加。這一趨勢正推動市場從傳統的經尿道切除術機器人輔助水刀消融術和前列腺尿道提升裝置等先進技術，而專注於這些平台的公司數量也在迅速成長。例如，PROCEPT BioRobotics公司在2024年2月報告稱，其2023會計年度機器人系統收入達到1.362億美元，年增82%。波士頓科學公司也宣布，其2023年泌尿系統和骨盆底健康領域的淨銷售額為19.5億美元，進一步印證了該技術的廣泛應用。

市場挑戰

良性前列腺增生（BPH）治療設備全球市場成長的主要挑戰在於先進手術技術所需的大量資金投入。最先進的雷射治療主機和機器人系統採集費用及持續維護成本高昂，構成了醫療機構推廣應用的重大經濟障礙，迫使預算緊張的醫療機構仔細評估此類高成本設備的投資回報率。考慮到初始成本與醫療機構的財務現實，許多醫療機構被迫推遲採購，繼續依賴經尿道切除術等更為傳統（成本更低）的方法，從而阻礙了更高效解決方案的市場滲透。

由於償還結構的收緊，可用於再投資的資金減少，使得證明這些高額資本投資合理性的難度進一步增加。據美國泌尿系統協會稱，2024年聯邦醫療保險（Medicare）醫生報銷係數將下降約3.37%，降至32.74美元，低於上年度。報銷率的下降直接影響泌尿系統診所和醫院的收入，嚴重限制了它們承擔先進良性前列腺增生治療系統相關高昂成本的能力，並直接阻礙了市場擴張。

市場趨勢

將人工智慧 (AI) 整合到機器人水刀消融系統中，標誌著一個變革性的轉折點。透過將機器學習演算法整合到機器人主機中，可以實現最佳化的治療計劃和即時組織切除，從而達到超越人類能力的精準度。這項技術利用龐大的解剖影像資料集，幫助外科醫生繪製前列腺輪廓，提高水刀消融術的安全性和一致性。例如，PROCEPT BioRobotics 公司於 2024 年 8 月宣布其人工智慧驅動的 HYDROS 機器人系統已獲得 FDA核准。該系統利用超過 5 萬個真實臨床數據點的洞察，為良性前列腺增生 (BPH) 的治療提供先進的影像引導和預測性工作流程。

同時，臨時性鎳鈦合金植入裝置的商業化正在改變微創治療方式，它無需永久植入，也不會造成熱損傷，即可緩解症狀。這些裝置能夠暫時再形成前列腺尿道，並因其能夠維持性功能和實現門診快速康復而日益普及，促使市場參與者積極爭取合約以確保市場准入。作為這一趨勢的象徵，奧林巴斯公司於2024年3月宣布，其鎳鈦合金臨時性裝置已在美國獲得13份集團採購組織（GPO）合約。這顯著擴大了這種非永久性治療方法的商業性應用範圍。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：良性前列腺增生（BPH）治療器材全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（雷射設備、微波設備、高頻設備、其他）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美良性前列腺增生（BPH）治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章 歐洲良性攝護腺增生（BPH）治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區良性攝護腺增生（BPH）治療器材市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章 中東和非洲良性前列腺增生（BPH）治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲良性攝護腺增生（BPH）治療設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球良性前列腺增生（BPH）治療設備市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Urologix, LLC
  • Olympus Corporation
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Zenflow Inc.
  • Sonablate Corporation
  • Richard Wolf Gmbh
  • Karl Storz SE
  • Terumo Medical Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20083

The Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is projected to expand from USD 11.56 Billion in 2025 to USD 14.98 Billion by 2031, reflecting a compound annual growth rate of 4.41%. This market comprises medical devices employed for both the minimally invasive and surgical management of enlarged prostate glands, including technologies such as resectoscopes, laser systems, and radiofrequency ablation devices. The primary catalysts driving this growth are a rapidly aging global population and a rising preference for minimally invasive procedures that facilitate faster patient recovery, a demand heavily influenced by the high incidence of BPH among older men. For instance, the American Urological Association reported in 2024 that the prevalence of benign prostatic hyperplasia and related lower urinary tract symptoms in men aged 65 and older ranged between 29% and 35%.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.56 Billion
Market Size 2031USD 14.98 Billion
CAGR 2026-20314.41%
Fastest Growing SegmentLaser based equipment
Largest MarketNorth America

Despite these positive demand metrics, a major obstacle hindering broader market expansion is the significant capital expenditure necessary for advanced surgical technologies. The high costs associated with acquiring and maintaining modern laser consoles and robotic systems can restrict adoption rates, particularly within healthcare facilities operating with tight procurement budgets. Consequently, this financial barrier frequently compels providers in cost-sensitive areas to depend on traditional, less efficient methodologies, thereby decelerating the penetration of newer equipment solutions.

Market Driver

The rising prevalence of benign prostatic hyperplasia is fundamentally propelled by the rapid aging of the global male population, requiring a sustained increase in the deployment of diagnostic and therapeutic equipment. As life expectancy increases, the number of patients needing intervention for lower urinary tract symptoms grows, necessitating that healthcare providers upgrade their urology departments to address this predictable and expanding addressable market for resectoscopes and ablation systems. According to the United Nations' "World Population Prospects 2024: Summary of Results" published in July 2024, the proportion of the global population aged 65 years or older is expected to increase to nearly 16% by 2050, significantly widening the primary demographic susceptible to prostate enlargement.

Alongside demographic changes, there is a distinct surge in demand for minimally invasive and non-surgical treatment options, driven by patient preference for procedures that offer reduced recovery times. This trend is steering the market toward advanced technologies, such as robotic-assisted waterjet ablation and prostatic urethral lift devices, and away from traditional transurethral resection, leading to substantial adoption rates for companies specializing in these platforms. For example, PROCEPT BioRobotics reported in February 2024 that revenue for their robotic systems reached $136.2 million for the fiscal year 2023, an 82% increase over the prior year, while Boston Scientific reported net sales of $1.95 billion for their Urology and Pelvic Health segment in 2023, further validating this technological uptake.

Market Challenge

The primary challenge inhibiting the growth of the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market is the substantial capital expenditure required for advanced surgical technologies. The significant acquisition and ongoing maintenance costs linked to modern laser consoles and robotic systems establish a formidable financial barrier to adoption, requiring healthcare facilities with constrained budgets to critically assess the return on investment for such capital-intensive equipment. When the upfront costs are balanced against hospital financial realities, many providers are forced to defer purchases and continue relying on traditional, less expensive methodologies like transurethral resection, which stalls the market penetration of more efficient solutions.

This difficulty in justifying high-value acquisitions is further aggravated by tightening reimbursement structures that diminish available capital for reinvestment. According to the American Urological Association, the Medicare Physician Fee Schedule conversion factor was reduced by approximately 3.37% in 2024, dropping to $32.74 from the previous year. Such reductions in payment rates directly affect the revenue streams of urology practices and hospitals, significantly restricting their ability to absorb the high costs associated with advanced BPH treatment systems and directly impeding market expansion.

Market Trends

The integration of Artificial Intelligence into Robotic Aquablation Systems marks a transformative shift, elevating procedural precision beyond human limitations by embedding machine learning algorithms into robotic consoles to optimize treatment planning and real-time tissue resection. This technology leverages extensive datasets of anatomical imagery to assist surgeons in mapping prostate contours, thereby improving safety and consistency during waterjet ablation. For instance, PROCEPT BioRobotics announced in August 2024 the FDA clearance of the HYDROS Robotic System, an AI-powered platform that utilizes insights from over 50,000 real-world procedures to provide advanced image guidance and predictive workflows for treating benign prostatic hyperplasia.

Concurrently, the commercialization of Temporary Implantable Nitinol Devices is reshaping minimally invasive therapies by providing symptom relief without the need for permanent implants or causing thermal damage. These devices, which temporarily reshape the prostatic urethra, are becoming increasingly popular due to their ability to preserve sexual function and facilitate rapid recovery in outpatient settings, leading market players to aggressively secure contracts to ensure accessibility. Highlighting this trend, Olympus announced in March 2024 that its temporary nitinol device had secured placement on 13 Group Purchasing Organization contracts in the United States, significantly broadening the commercial reach of this non-permanent therapeutic option.

Key Market Players

  • Urologix, LLC
  • Olympus Corporation
  • Boston Scientific Corporation
  • Teleflex Incorporated
  • Zenflow Inc.
  • Sonablate Corporation
  • Richard Wolf Gmbh
  • Karl Storz SE
  • Terumo Medical Corporation

Report Scope

In this report, the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Type

  • Laser-based Equipment
  • Microwave-based Equipment
  • Radiofrequency-based Equipment
  • Other

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By End user

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market.

Available Customizations:

Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Laser-based Equipment, Microwave-based Equipment, Radiofrequency-based Equipment, Other)
    • 5.2.2. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End user
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End user
    • 6.3.2. Canada Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End user
    • 6.3.3. Mexico Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End user

7. Europe Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End user
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End user
    • 7.3.2. France Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End user
    • 7.3.3. United Kingdom Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End user
    • 7.3.4. Italy Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End user
    • 7.3.5. Spain Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End user

8. Asia Pacific Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End user
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End user
    • 8.3.2. India Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End user
    • 8.3.3. Japan Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End user
    • 8.3.4. South Korea Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End user
    • 8.3.5. Australia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End user

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End user
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End user
    • 9.3.2. UAE Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End user
    • 9.3.3. South Africa Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End user

10. South America Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End user
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End user
    • 10.3.2. Colombia Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End user
    • 10.3.3. Argentina Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Benign Prostatic Hyperplasia (BPH) Treatment Equipment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Urologix, LLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Olympus Corporation
  • 15.3. Boston Scientific Corporation
  • 15.4. Teleflex Incorporated
  • 15.5. Zenflow Inc.
  • 15.6. Sonablate Corporation
  • 15.7. Richard Wolf Gmbh
  • 15.8. Karl Storz SE
  • 15.9. Terumo Medical Corporation

16. Strategic Recommendations

17. About Us & Disclaimer